Skip to main content
. 2020 Mar 11;15(3):e0229445. doi: 10.1371/journal.pone.0229445

Fig 4. Anti-RSPO3 OMP-131R10 is a therapeutic agent for lung and skin fibrosis.

Fig 4

A, Treatment scheme of OMP-131R10 in bleomycin-induced lung fibrosis model. B, Quantification of fibrosis using Ashcroft score. C, Quantification of lung collagen content. D, Representative Trichrome Staining on mouse lungs. E, Quantification of BAL leukocytes. F, Dermal thickness histology. G, Quantification of dermal thickness, myofibroblast content and hydroxyproline content. Skin fibrosis was induced by daily intradermal injections of bleomycin for 6 weeks. The mice were treated from day 14 with anti-RSPO3 (OMP-131R10) antibodies at 25 mg/kg once a week (n = 8 animals per group). At week 6, study was terminated and dermal thickness measured via histological methods data is shown as fold change in dermal thickness compared to the naïve. Data is shown as mean ± SEM. Statistical comparison was done using paired student t-tests. * p < 0.05.